Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
NEW IDENTITY: Known for its software, India has expanded into hardware, with its semiconductor industry growing from US$38bn in 2023 to US$45bn to US$50bn India on Saturday inaugurated its first semiconductor assembly and test facility, a milestone in the government’s push to reduce dependence on foreign chipmakers and stake a claim in a sector dominated by China. Indian Prime Minister Narendra Modi opened US firm Micron Technology Inc’s semiconductor assembly, test and packaging unit in his home state of Gujarat, hailing the “dawn of a new era” for India’s technology ambitions. “When young Indians look back in the future, they will see this decade as the turning point in our tech future,” Modi told the event, which was broadcast on his YouTube channel. The plant would convert
Nanya Technology Corp (南亞科技) yesterday said the DRAM supply crunch could extend through 2028, as the artificial intelligence (AI) boom has led the world’s major memory makers to dramatically reduce production of standard DRAM and allocate a significant portion of their capacity for high-bandwidth memory (HBM) chips. The most severe supply constraints would stretch to the first half of next year due to “very limited” increases in new DRAM capacity worldwide, Nanya Technology president Lee Pei-ing (李培瑛) told a news briefing. The company plans to increase monthly 12-inch wafer capacity to 20,000 in the first half of 2028 after a
Property transactions in the nation’s six special municipalities plunged last month, as a lengthy Lunar New Year holiday combined with ongoing credit tightening dampened housing market activity, data compiled by local land administration offices released on Monday showed. The six cities recorded a total of 10,480 property transfers last month, down 42.5 percent from January and marking the second-lowest monthly level on record, the data showed. “The sharp drop largely reflected seasonal factors and tighter credit conditions,” Evertrust Rehouse Co (永慶房屋) deputy research manager Chen Chin-ping (陳金萍) said. The nine-day Lunar New Year holiday fell in February this year, reducing
Zimbabwe’s ban on raw lithium exports is forcing Chinese miners to rethink their strategy, speeding up plans to process the metal locally instead of shipping it to China’s vast rechargeable battery industry. The country is Africa’s largest lithium producer and has one of the world’s largest reserves, according to the US Geological Survey (USGS). Zimbabwe already banned the export of lithium ore in 2022 and last year announced it would halt exports of lithium concentrates from January next year. However, on Wednesday it imposed the ban with immediate effect, leaving unclear what the lithium mining sector would do in the
RSS